Rituximab in B-Cell Hematologic Malignancies: A Review of 20 Years of Clinical Experience. / (Record no. 1166)
[ view plain ]
| 000 -LEADER | |
|---|---|
| fixed length control field | 04297naa a22005897i 4500 |
| 001 - CONTROL NUMBER | |
| control field | UMUN-OA-20261005-MLS-024 |
| 003 - CONTROL NUMBER IDENTIFIER | |
| control field | local |
| 005 - DATE AND TIME OF LATEST TRANSACTION | |
| control field | 20261005174903.0 |
| 006 - FIXED-LENGTH DATA ELEMENTS--ADDITIONAL MATERIAL CHARACTERISTICS | |
| fixed length control field | m o d |
| 007 - PHYSICAL DESCRIPTION FIXED FIELD--GENERAL INFORMATION | |
| fixed length control field | cr|||||||||||| |
| 008 - FIXED-LENGTH DATA ELEMENTS--GENERAL INFORMATION | |
| fixed length control field | 261005s2017 xx o u000 0 eng d |
| 024 7# - OTHER STANDARD IDENTIFIER | |
| Standard number or code | 10.1007/s12325-017-0612-x |
| Source of number or code | doi |
| 035 ## - SYSTEM CONTROL NUMBER | |
| System control number | (local)EuropePMC:PMC5656728 |
| 040 ## - CATALOGING SOURCE | |
| Original cataloging agency | local |
| Language of cataloging | eng |
| Transcribing agency | local |
| 041 0# - LANGUAGE CODE | |
| Language code of text/sound track or separate title | eng |
| 100 0# - MAIN ENTRY--PERSONAL NAME | |
| Personal name | Gilles Salles |
| Relator term | author. |
| 245 10 - TITLE STATEMENT | |
| Title | Rituximab in B-Cell Hematologic Malignancies: A Review of 20 Years of Clinical Experience. / |
| Statement of responsibility, etc. | Gilles Salles; Martin Barrett; Robin Foà [and others]. |
| 264 #1 - PRODUCTION, PUBLICATION, DISTRIBUTION, MANUFACTURE, AND COPYRIGHT NOTICE | |
| Place of production, publication, distribution, manufacture | [Place of publication not identified] : |
| Name of producer, publisher, distributor, manufacturer | [publisher not identified], |
| Date of production, publication, distribution, manufacture, or copyright notice | 2017. |
| 300 ## - PHYSICAL DESCRIPTION | |
| Extent | 1 online resource (1 article). |
| 336 ## - CONTENT TYPE | |
| Content type term | text |
| Content type code | txt |
| Source | rdacontent |
| 337 ## - MEDIA TYPE | |
| Media type term | computer |
| Media type code | c |
| Source | rdamedia |
| 338 ## - CARRIER TYPE | |
| Carrier type term | online resource |
| Carrier type code | cr |
| Source | rdacarrier |
| 500 ## - GENERAL NOTE | |
| General note | Publication type: Review article. |
| 500 ## - GENERAL NOTE | |
| General note | Linked open-access copy: published version. |
| 506 0# - RESTRICTIONS ON ACCESS NOTE | |
| Terms governing access | Open access; no subscription required for the linked open-access version. |
| Standardized terminology for access restriction | Unrestricted online access |
| Source of term | star |
| 520 3# - SUMMARY, ETC. | |
| Summary, etc. | Rituximab is a human/murine, chimeric anti-CD20 monoclonal antibody with established efficacy, and a favorable and well-defined safety profile in patients with various CD20-expressing lymphoid malignancies, including indolent and aggressive forms of B-cell non-Hodgkin lymphoma. Since its first approval 20 years ago, intravenously administered rituximab has revolutionized the treatment of B-cell malignancies and has become a standard component of care for follicular lymphoma, diffuse large B-cell lymphoma, chronic lymphocytic leukemia, and mantle cell lymphoma. For all of these diseases, clinical trials have demonstrated that rituximab not only prolongs the time to disease progression but also extends overall survival. Efficacy benefits have also been shown in patients with marginal zone lymphoma and in more aggressive diseases such as Burkitt lymphoma. Although the proven clinical efficacy and success of rituximab has led to the development of other anti-CD20 monoclonal antibodies in recent years (e.g., obinutuzumab, ofatumumab, veltuzumab, and ocrelizumab), rituximab is likely to maintain a position within the therapeutic armamentarium because it is well established with a long history of successful clinical use. Furthermore, a subcutaneous formulation of the drug has been approved both in the EU and in the USA for the treatment of B-cell malignancies. Using the wealth of data published on rituximab during the last two decades, we review the preclinical development of rituximab and the clinical experience gained in the treatment of hematologic B-cell malignancies, with a focus on the well-established intravenous route of administration. This article is a companion paper to A. Davies, et al., which is also published in this issue. Funding F. Hoffmann-La Roche Ltd., Basel, Switzerland. |
| 540 ## - TERMS GOVERNING USE AND REPRODUCTION NOTE | |
| Terms governing use and reproduction | Creative Commons Attribution-NonCommercial. See the linked licence for the applicable terms. |
| Uniform Resource Identifier | <a href="https://creativecommons.org/licenses/by-nc/4.0/">https://creativecommons.org/licenses/by-nc/4.0/</a> |
| 546 ## - LANGUAGE NOTE | |
| Language note | In English. |
| 588 0# - SOURCE OF DESCRIPTION NOTE | |
| Source of description note | Description generated from Europe PMC bibliographic metadata retrieved on 5 October 2026; full text linked from the source. |
| 590 ## - LOCAL NOTE (RLIN) | |
| Local note | Course allocation: B. Sc. Medical Laboratory Science. |
| 650 #4 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Safety |
| 650 #4 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Monoclonal antibody |
| 650 #4 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | CD20 |
| 650 #4 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Treatment outcome |
| 650 #4 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Follicular Lymphoma |
| 650 #4 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Rituximab |
| 653 ## - INDEX TERM--UNCONTROLLED | |
| Uncontrolled term | B. Sc. Medical Laboratory Science |
| 653 ## - INDEX TERM--UNCONTROLLED | |
| Uncontrolled term | UMUN open access collection |
| 653 ## - INDEX TERM--UNCONTROLLED | |
| Uncontrolled term | hematology |
| 655 #4 - INDEX TERM--GENRE/FORM | |
| Genre/form data or focus term | Review articles. |
| 700 0# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Martin Barrett |
| Relator term | author. |
| 700 0# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Robin Foà |
| Relator term | author. |
| 700 0# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Joerg Maurer |
| Relator term | author. |
| 700 0# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Susan O'Brien |
| Relator term | author. |
| 700 0# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Nancy Valente |
| Relator term | author. |
| 700 0# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Michael Wenger |
| Relator term | author. |
| 700 0# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | David G Maloney |
| Relator term | author. |
| 773 0# - HOST ITEM ENTRY | |
| Title | Advances in therapy |
| Related parts | Vol. 34, no. 10, (2017), pages/article 2232-2273 |
| International Standard Serial Number | 0741-238X |
| 856 40 - ELECTRONIC LOCATION AND ACCESS | |
| Uniform Resource Identifier | <a href="https://europepmc.org/articles/PMC5656728">https://europepmc.org/articles/PMC5656728</a> |
| Link text | Read open-access publication |
| Public note | Open access. |
| Access status | 0 |
| 884 ## - DESCRIPTION CONVERSION INFORMATION | |
| Conversion process | Course selection and automated MARC21 enrichment from Europe PMC metadata. |
| Conversion date | 20261005 |
| Identifier of source metadata | https://europepmc.org/articles/PMC5656728 |
| Conversion agency | local |
| 942 ## - ADDED ENTRY ELEMENTS (KOHA) | |
| Suppress in OPAC | No |
No items available.